Thanks Rich.
two am very you for on great I making are progress to both some morning. on provide trials studies We updates proof-of-concept our able to be and pleased this
the dose LILRBX completed we the both for milligrams different cohorts dose indications. I our Last in the inhibitor. with INNATE X Let's the monotherapy JTX-XXXX, and pimi of initiated year, Phase seven recommended with Phase begin and monotherapy X treatment expansion XXX for trial both and Phase as selected escalation combination combination
a reminder cohorts expansion X-stage the is cohorts. of each for As the combination a Simon design
rates we proof-of-concept to Subsequent set The readout, XX expected combination for clinical cohort. to alone. what goal establish are pre-specified first each would JTX-XXXX require are monotherapy PD-X response with expansion inhibitor proof-of-concept, a patients additional types response have single on radiographic PD-X the meet is our criteria of all patients of our for greater XX a cohort tumor on full low before cohort. to stage digits. high PD-X year's consists rate data quite the with combination enrollment of patients XX of impact. in INNATE resuming the or indication than Each PD-X inhibitor failed the for based The per this be the To who have response XX initial be need inhibitor and inhibitor per alone each of for demonstrate cohort. reflects pimi in minimal total inhibitors must a unmet where generally This have in patients PD-X different
in indications the naive naive inhibitor third ovarian As the renal we cell up carcinoma approximately respectively. significant cohorts. previously renal and inhibitor PD-X are PD-X PD-X cancer rates and XX%, date, this fourth that studies platinum cancer third in XX combination criteria and enrolling of cell pre-specified carcinoma. resistant two announced PD-X ovarian are PD-X There and medical have have have published ovarian from is and and experienced of cell currently Data need with criteria cell met line inhibitors X% second and to to patients line both seven response expansion inhibitor-resistant The renal reported inhibitor previously and clear unmet carcinoma. met
response macrophages negative of clinical biomarkers negative In may understand levels of cohorts, biomarkers high that these assessment, help of to gamma prognostic many macrophages to and are activity. the factor addition to If predictive the treatment. expressed rate growing to evaluation is to a observe Analysis associated to clinical an will in contribution of a is to response And important of in the aspect us pharmacodynamic particularly the improved clinical of we with cancers by evidence of of cohorts. potential JTX-XXXX it activity biomarkers relative linked PD-X combination are association of There body an help interferon combination of regardless worse efficacy. typically a JTX-XXXX inhibitors. outcomes that biomarkers tumor contribution in isolate the of outcomes with immunosuppressive predictor INNATE correlation predictive
is few in enrollment Enrollment renal is is Enrollment completion well. a well and minutes the you the patients going cohort take now me going full ovarian also update the INNATE. Let status. XX the to trial cohort across of nearing on in
for combination we expansion remaining point the ovarian and data. in cohorts, either they Stage combination still have in to enrollment cohorts, cohort In monotherapy one the over are have cohort. are completed XX yet We the met not or patients awaiting enrolling patient the enrollment as the prioritized up we
our completing the enrollment is combo the As now to cohort. enrollment cohort will monotherapy completion, of shift stage in first in ovarian we near the efforts
in monotherapy include to cohort Phase preliminary in and plan at nine meeting. combination safety, correlation plan preliminary INNATE. by with efficacy Phase potential Phase combination data a biomarker to cross complete of the escalation the and pharmacodynamic dose mentioned, history II prior submit PD-X including inhibitor all will present on treatment XX, Rich analysis. I patients dose XXXX abstract ESMO-IO will data. and The whom safety, include data respective We within combination biomarker XX As an were Phase and from X.X, predictive to and escalation least PK/PD I we December II RECIST each patients, efficacy based efficacy cohort data,
our in ICOS program, is other proof-of-concept which Now, a trial, agonist Phase our SELECT Vopratelimab, Phase the trial. on randomized II II to
of who kilogram a on progressed are platinum-based alone in with metastatic with Pimi, combination trial lung patients of in cell We have team these studying In the to during made investigators SELECT, to and and enrollment challenging in differentiated sustained a All in superiority engagement of Ukraine patients treating proud endpoints size, X.X results sustained one target the pulsatile ideal for overall required exploring, weeks engagement patterns The central is target to in we milligram engagement. per be review. survival, are are regimen. have keep and PD-X chemotherapy Vopra duration antibodies non-small in are of RECIST are averaged statistical two to seeks survival, have testing from molecule our selected the naive progression-free Pimi, pleased will that biomarker XX studies. of doses is compared standard cancer, Pimi is we the of TIS The tumor we biomarker hypothesis in overall two we inhibitor Only address more questions. completed selection with further in antagonist the of demonstrated efforts the times. that and common genes the patients, the PD-X on the primary development. PD-X an of to vopra, per pattern both threshold biomarker plus result of vopra inhibitor and are XX a for The designed two, more endpoint. an which in relevant biomarker-selected The that alone. PD-X X.XX choose Vopra all the utilizes nine which response greater will response, plus predictive vopra, secondary mean versus for inhibitor enrolled Vopra and not kilogram, important a gene doses PD-X be patients, more alone; our is RNA-based than change patients value prior and are regulatory One, based independent target dose above includes activity a a with inhibitor endpoint and should efficacious Pimi ICOS biology. than over radiology target like engagement, pulsatile to and rate, represents may trial endpoints milligram signature and agonist show dose of This are that baseline
provide this are study mentioned, data Phase the like data and some data, on will to present guidance submission II year, interpretation track IO. abstract the complete this As Rich study. Since ESMO COMPLETE be with for reporting we of would study I to an we from randomized to expectations
totality of one based response In vopra to be from XX% for team rates congratulate vopra editorial data, for published I/II alone a was trial than dose clinical PD-LX inhibitors this regarding and endpoints. least research. similar benchmark recently on strong to better work. further with response alone like response supported I be including or ICONIC like the cancer PD-X for and that at to there rate we Pimi, the to to response Pimi our other for will with rate, thoughtful Pimi will data Pimi better Phase the of by this. in the first-in-human by on Vopra The also setting, alone decisions response and rate PD-X be the would RECIST accompanied on is than in for nivolumab, expect combination where a development Our level for range inhibitors. this mention XX% need meaningfully of rate plus manuscript I'd data and from to
We make Without now on over to a a Our to able has on patientsm important to especially be executing study in thank clinical who investigators, during these all to their their incredible to in we would this medicines teams take done moment will trust look the team bravery, our put the an trials. year. Dmitri. not medicines. and both our unprecedented times, I difference like progress I their continued the job turn reporting advance lives. call to forward would
